Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy

Most approaches targeting the immune system against tumors have focused on patients with established tumors. However, whether the immune system can recognize preneoplastic stages of human cancer is not known. Here we show that patients with preneoplastic gammopathy mount a vigorous T cell response to autologous premalignant cells. This preneoplasia-specific CD4+ and CD8+ T cell response is detected in freshly isolated T cells from the BM. T cells from myeloma marrow lack this tumor-specific rapid effector function. These data provide direct evidence for tumor specific immune recognition in human preneoplasia and suggest a possible role for the immune system in influencing the early growth of transformed cells, long before the development of clinical cancer.

• Publication year

  2003

• Venue

  Journal of Experimental Medicine

• Publication date

  2003-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1084/jem.20031030PMID 14638846PMCID 2194131
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Does the immune system see tumors as foreign or self?

  2003cited by this paper
• Immune Enhancement of Skin Carcinogenesis by CD4+ T Cells

  2003cited by this paper
• Immune Enhancement of Skin Carcinogenesis by CD4 (cid:2) T Cells

  2003cited by this paper
• Gene expression profiles of human breast cancer progression

  2003cited by this paper
• A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma

  2003influential reference
• A molecular signature of metastasis in primary solid tumors

  2003cited by this paper
• Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy.

  2002cited by this paper
• Genomic abnormalities in monoclonal gammopathy of undetermined significance.

  2002cited by this paper
• Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells

  2002cited by this paper
• Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.

  2002cited by this paper
• A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

  2002influential reference
• T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells

  2002influential reference
• Multiple myeloma: evolving genetic events and host interactions

  2002cited by this paper
• T-cell response to unique and shared antigens and vaccination of cancer patients.

  2002cited by this paper
• Prophylactic cancer vaccines.

  2002cited by this paper
• Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow

  2001cited by this paper
• Requirement for reverse immune surveillance for the growth of germinal center-derived murine lymphomas.

  2000cited by this paper
• Enhanced Growth of Primary Tumors in Cancer-Prone Mice after Immunization against the Mutant Region of an Inherited Oncoprotein

  2000cited by this paper
• T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.

  2000cited by this paper
• Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.

  1999cited by this paper
• An Expanded Peripheral T Cell Population to a Cytotoxic T Lymphocyte (Ctl)-Defined, Melanocyte-Specific Antigen in Metastatic Melanoma Patients Impacts on Generation of Peptide-Specific Ctls but Does Not Overcome Tumor Escape from Immune Surveillance in Metastatic Lesions

  1999cited by this paper
• Tumor-specific killer cells in paraneoplastic cerebellar degeneration

  1998cited by this paper
• Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis.

  1998cited by this paper
• Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes

  1998cited by this paper
• Tumor immunology: the glass is half full.

  1998influential reference
• Idiotype‐specific T lymphocytes in monoclonal gammopathies: evidence for the presence of CD4+ and CD8+ subsets

  1997cited by this paper
• Peripheral T cell tolerance as a tumor escape mechanism: deletion of CD4+ T cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmacytoma

  1996cited by this paper
• T cells induce terminal differentiation of transformed B cells to mature plasma cell tumors.

  1995cited by this paper
• Stimulatory effects of immune reactions upon the growths of untransplanted tumors.

  1994cited by this paper
• gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro.

  1993cited by this paper
• gamma-Interferon in multiple myeloma: inhibition of interleukin-6 (IL- 6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro

  1993cited by this paper
• Specific pathogen-free BALB/cAn mice are refractory to plasmacytoma induction by pristane.

  1991cited by this paper
• Lysis of autologous melanoma cells by tumor-infiltrating lymphocytes: association with clinical response.

  1991cited by this paper
• Interferon-gamma regulates the T cell response to precursor nevi and biologically early melanoma.

  1987cited by this paper
• Hematology : principles and practice

  1972cited by this paper

• Sex differences in the clinical presentation of patients with newly diagnosed multiple myeloma

  2026cites this paper
• Current Anti-Myeloma Chimeric Antigen Receptor-T Cells: Novel Targets and Methods

  2025cites this paper
• Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists.

  2025cites this paper
• Immune Alterations in Myeloma Evolution and Outcomes: Quo Vadis?

  2025cites this paper
• mRNA cancer vaccine: A novel and potential immunotherapy for multiple myeloma.

  2025cites this paper
• Vaccination in Multiple Myeloma: Challenges and Strategies

  2025cites this paper
• Smoldering multiple myeloma: Integrating biology and risk into management.

  2024cites this paper
• T Cell Exhaustion Markers in Multiple Myeloma Patients are Lower After Physical Activity Intervention.

  2024cites this paper
• Regulatory T cells suppress myeloma-specific immunity during autologous stem cell mobilization and transplantation

  2024cites this paper
• SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma.

  2024cites this paper
• Immunocompetent mouse models of multiple myeloma.

  2024cites this paper
• Immune-Pathogenesis of Myeloma.

  2024cites this paper
• Immune status and selection of patients for immunotherapy in myeloma: a proposal

  2024cites this paper
• Bispecific antibodies in the treatment of multiple myeloma

  2024cites this paper
• CAR-T cell therapy in Multiple Myeloma: current status and future challenges

  2024cites this paper
• Rough neighborhood: Intricacies of cancer stem cells and infiltrating immune cell interaction in tumor microenvironment and potential in therapeutic targeting.

  2023cites this paper
• Dissecting molecular mechanisms of immune microenvironment dysfunction in multiple myeloma and precursor conditions

  2023cites this paper
• Monoclonal Gammopathies and the Bone Marrow Microenvironment: From Bench to Bedside and Then Back Again

  2023cites this paper
• Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancy

  2023cites this paper
• Uptake of long-chain fatty acids from the bone marrow suppresses CD8+ T-cell metabolism and function in multiple myeloma

  2023cites this paper
• Prognostic Relevance of Multi-Antigenic Myeloma-Specific T-Cell Assay in Patients with Monoclonal Gammopathies

  2023cites this paper
• Then and NowHarnessing Immunity in Myeloma: Wine That Keeps Getting Better?

  2023cites this paper
• Multiplex immunohistochemistry elucidates increased distance between cytotoxic T cells and plasma cells in relapsed myeloma, and identifies Lag-3 as the most common checkpoint receptor on cytotoxic T cells of myeloma patients.

  2023cites this paper
• CAR-T Therapy in Relapsed Refractory Multiple Myeloma

  2023cites this paper
• Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance Efficacy and Improve Safety

  2023cites this paper
• Anti-BCMA Immunotherapy in Myeloma: Is It the Tumor or the Immune System That Most Undermines Outcomes?

  2022cites this paper
• The Role of T Cell Immunity in Monoclonal Gammopathy and Multiple Myeloma: From Immunopathogenesis to Novel Therapeutic Approaches

  2022cites this paper
• Multiple Myeloma Therapy: Emerging Trends and Challenges

  2022cites this paper
• The evolution of immune dysfunction in multiple myeloma

  2022influential citation
• BCMA-targeted therapies for multiple myeloma: strategies to maximize efficacy and minimize adverse events

  2022cites this paper
• High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments.

  2022cites this paper
• Langerhans dendritic cell vaccine bearing mRNA-encoded tumor antigens induces antimyeloma immunity after autotransplant

  2022cites this paper
• Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?

  2022cites this paper
• Extracellular Vesicles in Multiple Myeloma—Cracking the Code to a Better Understanding of the Disease

  2022cites this paper
• Immune Phenotypes and Target Antigens of Clonally Expanded Bone Marrow T Cells in Treatment-Naïve Multiple Myeloma

  2022cites this paper
• Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.

  2022cites this paper
• The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception

  2022cites this paper
• Bystander Memory T Cells and IMiD/Checkpoint Therapy in Multiple Myeloma: A Dangerous Tango?

  2021cites this paper
• Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia.

  2021cites this paper
• Aberrant extrafollicular B cells, immune dysfunction, myeloid inflammation and MyD88-mutant progenitors precede malignancy in Waldenstrom macroglobulinemia

  2021cites this paper
• The Immune Microenvironment in Multiple Myeloma: Friend or Foe?

  2021cites this paper
• Co-evolution of Immune Response in Multiple Myeloma: Implications for Immune Prevention

  2021cites this paper
• Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD Negativity

  2021cites this paper
• The evolving status of immunotherapies in multiple myeloma: the future role of bispecific antibodies

  2021cites this paper
• An Unconventional View of T Cell Reconstitution After Allogeneic Hematopoietic Cell Transplantation

  2021cites this paper
• V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma

  2021cites this paper
• Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma

  2021cites this paper
• Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?

  2021cites this paper
• Case of Kikuchi-Fujimoto disease associated with multiple myeloma

  2021cites this paper
• Progress in the Management of Smoldering Multiple Myeloma

  2021cites this paper
• Single-cell transcriptional analysis of the immune tumour microenvironment during myeloma disease evolution

  2021cites this paper
• The Cancer-Immunity Cycle in Multiple Myeloma

  2021cites this paper
• Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma

  2020cites this paper
• NK and NKT Cell-Mediated Immune Surveillance against Hematological Malignancies

  2020cites this paper
• Actors on the Scene: Immune Cells in the Myeloma Niche

  2020cites this paper
• Cancer immunoediting and immune dysregulation in multiple myeloma.

  2020cites this paper
• Differential effects of PD-L1 versus PD-1 blockade on myeloid inflammation in human cancer.

  2020cites this paper
• Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview

  2020cites this paper
• An Introduction to CAR Immunotherapy

  2020cites this paper
• Bone Marrow Stromal Cells-Induced Drug Resistance in Multiple Myeloma

  2020cites this paper
• Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.

  2020cites this paper
• Summary of the 2019 BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.

  2020cites this paper
• Immunotherapy of multiple myeloma.

  2020cites this paper
• Therapeutic targets in myeloma bone disease

  2020cites this paper
• Fighting microbial pathogens by integrating host ecosystem interactions and evolution

  2020cites this paper
• Summary of the 2019 BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling

  2020cites this paper
• Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials

  2020cites this paper
• Current and emerging immunotherapeutic approaches to the treatment of multiple myeloma

  2019cites this paper
• Moving Immunoprevention Beyond Virally Mediated Malignancies: Do We Need to Link It to Early Detection?

  2019cites this paper
• Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy

  2019cites this paper
• Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma

  2019cites this paper
• B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma.

  2019cites this paper
• Chemotherapy followed by anti-CD137 mAb immunotherapy improves disease control in a mouse myeloma model.

  2019cites this paper
• Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy.

  2019cites this paper
• Monoclonal gammopathy of undetermined significance.

  2019cites this paper
• T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma.

  2019cites this paper
• Immunotherapy in Multiple Myeloma

  2019cites this paper
• Natural killer cells, multiple myeloma, and daratumumab : a love-hate relationship

  2019cites this paper
• How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma

  2019cites this paper
• Lymphocyte Subsets and Inflammatory Cytokines of Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma

  2019cites this paper
• Immunopathogenesis and immunotherapy of multiple myeloma

  2018cites this paper
• Identification and characterization of HLA-A24-specific XBP1, CD138 (Syndecan-1) and CS1 (SLAMF7) peptides inducing antigens-specific memory cytotoxic T lymphocytes targeting multiple myeloma

  2018cites this paper
• Maintaining therapeutic progress in multiple myeloma by integrating genetic and biological advances into the clinic

  2018cites this paper
• Chapter 4 Malignant Interaction between B Cells and T Helper Cells

  2018cites this paper
• Bone marrow endothelial cells sustain a tumor-specific CD8+ T cell subset with suppressive function in myeloma patients

  2018cites this paper
• PD1 is expressed on exhausted T cells as well as virus specific memory CD8+ T cells in the bone marrow of myeloma patients

  2018cites this paper
• Bone marrow T helper cells with a Th1 phenotype induce activation and proliferation of leukemic cells in precursor B acute lymphoblastic leukemia patients

  2018cites this paper
• Characterization of CD4+ T cell-mediated cytotoxicity in patients with multiple myeloma.

  2018cites this paper
• Targeting Intrinsic and Extrinsic Vulnerabilities for the Treatment of Multiple Myeloma

  2017cites this paper
• Integration of Genomics Into Treatment: Are We There Yet?

  2017cites this paper
• Systematic evaluation of immune regulation and modulation

  2017cites this paper
• Malignant Interaction between B Cells and T Helper Cells

  2017cites this paper
• Hematologic Malignancies: Plasma Cell Disorders.

  2017cites this paper
• Changes in bone marrow innate lymphoid cell subsets in monoclonal gammopathy: target for IMiD therapy.

  2017cites this paper
• Precancer Atlas to Drive Precision Prevention Trials.

  2017cites this paper
• Inflammation and Cancer

  2017cites this paper
• Pediatric precursor B acute lymphoblastic leukemia: are T helper cells the missing link in the infectious etiology theory?

  2017cites this paper
• Multiple Myeloma and the Immune Microenvironment.

  2017cites this paper
• The concept of immune surveillance against tumors: The first theories

  2016cites this paper
• Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.

  2016cites this paper